With low valuations and no debt, this drug maker earn top scores in a Ben Graham value screen.
Not the typical turnaround pick, this company has a problem with investor perceptions.
Orexigen, once the leading candidate to reach market, expects two more years of safety testing.
The pharmaceutical leader offers a consistent track record, strong new product pipeline, and generous yield.
The acquisition is a vote of confidence in Isis Pharmaceuticals' drug development technology.
This stock meets the investing criteria of the Fidelity Magellan Fund's legendary manager.
The two drug companies end a rocky 10-year partnership. What's next for Amylin?
VIDEO ON MSN MONEY
Copyright © 2013 Microsoft. All rights reserved.
Quotes are real-time for NASDAQ, NYSE and AMEX. See delay times for other exchanges.
Fundamental company data and historical chart data provided by Thomson Reuters (click for restrictions). Real-time quotes provided by BATS Exchange. Real-time index quotes and delayed quotes supplied by Interactive Data Real-Time Services. Fund summary, fund performance and dividend data provided by Morningstar Inc. Analyst recommendations provided by Zacks Investment Research. StockScouter data provided by Verus Analytics. IPO data provided by Hoover's Inc. Index membership data provided by SIX Financial Information.
All hail the bull market, which ended the week with a big rally. But it also is starting to look a little like 1987, which suffered an epic blow-out.
The Market Dispatches column has been discontinued. Here's where to find the latest stock and business news on MSN Money, and the latest from market writer Charley Blaine.
MONEY & POLITICS
Breaking up big banks is an untested solution to the too big to fail problem that attempts to isolate and dismantle large, troubled institutions while protecting the rest of the economy.
The IRS is struggling to combat identify thieves who file fraudulent tax returns in the names of older residents who don't need to file.